In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

Targeting the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis with monoclonal antibodies (mAbs) represents a crucial breakthrough in anticancer therapy, but mAbs are limited by their poor oral bioavailability, adverse events in multiple organ systems, and primary, ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chih-Hao, Chung, Wei-Min, Tsai, Chun-Hao, Cheng, Ju-Chien, Hsu, Kai-Cheng, Tzeng, Huey-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741796/
https://www.ncbi.nlm.nih.gov/pubmed/34996924
http://dx.doi.org/10.1038/s41598-021-03590-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741796/
https://www.ncbi.nlm.nih.gov/pubmed/34996924
http://dx.doi.org/10.1038/s41598-021-03590-4

Ejemplares similares